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Purpose: To assess and compare the levels of functioning in patients with major depressive 
disorder treated with either duloxetine with a daily dose of #60 mg or a selective serotonin 
reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic setting in East 
Asia. In addition, this study examined the impact of painful physical symptoms (PPS) on the 
effects of these treatments.
Patients and methods: Data for this post hoc analysis were taken from a 6-month prospec-
tive observational study involving 1,549 patients with major depressive disorder without sexual 
dysfunction. The present analysis focused on a subgroup of patients from East Asia (n=587). 
Functioning was measured using the Sheehan Disability Scale (SDS). Depression severity was 
assessed using the 16-item Quick Inventory of Depressive Symptomatology-Self Report. PPS 
were rated using the modified Somatic Symptom Inventory. A mixed model with repeated 
measures was fitted to compare the levels of functioning between duloxetine-treated (n=227) 
and SSRI-treated (n=225) patients, adjusting for baseline patient characteristics.
Results: The mean SDS total score was similar between the two treatment cohorts (15.46 
[standard deviation =6.11] in the duloxetine cohort and 16.36 [standard deviation =6.53] in 
the SSRI cohort, P=0.077) at baseline. Both descriptive and regression analyses confirmed 
improvement in functioning in both groups during follow-up, but duloxetine-treated patients 
achieved better functioning. At 24 weeks, the estimated mean SDS total score was 4.48 (standard 
error =0.80) in the duloxetine cohort, which was statistically significantly lower (ie, better func-
tioning) than that of 6.76 (standard error =0.77) in the SSRI cohort (P,0.001). This treatment 
difference was more apparent in the subgroup of patients with PPS at baseline. Similar patterns 
were also observed for SDS subscores (work, social life, and family life).
Conclusion: Depressed patients treated with duloxetine achieved better functioning compared 
to those treated with SSRIs. This treatment difference was mostly driven by patients with PPS 
at baseline.
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Introduction
Depression is one of the most prevalent, disabling, and costly mental disorders, currently 
affecting nearly 350 million people worldwide.1 The Global Burden of Disease 2010 
study identified depression as a leading cause of burden, accounting for 40.5% of 
disability-adjusted life years associated with mental and substance-use disorders.2 The 
economic burden of depression also appeared to be substantial even in nonwestern coun-
tries. For instance, the total costs of depression were estimated to be over US$6 billion 
in People’s Republic of China (2002 value),3 ¥2 trillion in Japan (2005 value),4 and 
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US$4 million in South Korea (2005 value).5 Notably, morbid-
ity costs, arising from productivity loss due to absenteeism 
and presenteeism, far exceeded treatment costs of depression 
in all studies, implying significant impairment in functioning 
and quality of life in patients with depression.
Indeed, ~60% of patients with major depressive disorder 
(MDD) were reported to have severe functional impairment 
such as disruption in physical, social, and occupational 
functioning,6 and a similar proportion of the patients were also 
reported to have severe impairment in quality of life.7 This 
evidence reflects a substantial unmet need in the treatment 
of MDD, especially from a patient’s perspective. Notably, 
return to a normal level of functioning is often reported by 
patients as more important than symptom-related outcomes.8 
While the importance of normalization of functioning is 
increasingly recognized in the treatment of MDD, functional 
outcomes are still frequently excluded when evaluating the 
effects of MDD treatments. Without functioning assessment, 
however, the effects of MDD treatments may not be fully 
captured because functional impairment in patients with 
MDD often lags behind the resolution of clinical symptoms,9 
and more importantly, residual functional impairment could 
increase the risk of MDD relapse.10–12
Painful physical symptoms (PPS) such as headache, 
abdominal pain, heart/chest pain, and back pain often accom-
pany the emotional symptoms of MDD; up to 76% of patients 
with MDD have been reported to have such symptoms,13–17 
and the majority of them have also been reported to have mul-
tiple pain complaints.18 Not surprisingly, previous research 
has shown that these symptoms can severely interfere with 
daily functioning and quality of life in patients with MDD.19,20 
Return to normal functioning in MDD could therefore be 
heavily influenced by the extent of PPS control.20
Duloxetine hydrochloride is a potent and relatively bal-
anced inhibitor of a potent and relatively bal anced serotonin-
norepinephrine reuptake inhibitor (SNRI).21 It has been 
approved for the management of MDD, generalized anxiety 
disorder, fibromyalgia, diabetic peripheral neuropathic pain 
(DPNP), and chronic musculoskeletal pain in the United 
States, and also for the management of some or all of the indi-
cations in many other countries worldwide, including Asian 
countries, most recently in Japan (for MDD and DPNP). 
The findings from clinical trials have shown that treatment 
with duloxetine improves clinical outcomes in patients with 
MDD.22–24 In particular, in line with its pain-related indica-
tions, the effects of duloxetine, compared to other classes 
of antidepressants, have been found to be more apparent 
in a subgroup of MDD patients with PPS.25–27 It has been 
suggested that the dual action of SNRIs may be more effec-
tive than those that inhibit only one monoamine at least for 
patients suffering from both depression and pain,25–27 given 
the hypothesis that the pathophysiology of both conditions 
involves an imbalance of serotonin and norepinephrine.15 
Nevertheless, more research is warranted to determine the 
relative effects of SNRIs and other classes of antidepressants 
at least in this subgroup.
The present post hoc analysis examined the course of 
impaired functioning during the treatment of patients with 
MDD and compared the level of functioning in patients 
treated with duloxetine or a selective serotonin reuptake 
inhibitor (SSRI) for up to 6 months in a naturalistic set-
ting in East Asia, using data from a 6-month prospective 
observational study. Functioning was measured using the 
Sheehan Disability Scale (SDS), which is a brief self-report 
inventory that assesses functional impairment in work/school, 
social life, and family life.28 It is believed to be one of the 
most effective measures of functional impairment because 
of its sensitivity in detecting treatment effects and its ease 
of use.29 In Japan, the daily dose of duloxetine is limited 
to a maximum of 60 mg/day for the treatment of MDD. 
Although our study did not include Japan, we also limited 
the maximum dose of duloxetine to 60 mg/day to ensure 
that our results have broader implications across East Asia 
including Japan. In addition, given the link between pain 
and functional impairment, we also performed subgroup 
analyses for patients with and without PPS at baseline to 
examine whether treatment effects on functioning vary by 
PPS status.
Patients and methods
Data and study sample
Data for this post hoc analysis were taken from a 6-month, 
international, prospective, noninterventional, observational 
study, primarily designed to examine treatment-emergent 
sexual dysfunction and other treatment outcomes among 
patients with MDD who were treated with either an SSRI or 
an SNRI in actual clinical practice. A total of 1,647 patients 
were enrolled at 88 sites between November 15, 2007, and 
November 28, 2008. Of these, 1,549 patients were classified 
as “sexually active patients without sexual dysfunction at 
study entry” and included in the study. The present analy-
sis focused only on those patients from East Asia (n=587) 
(People’s Republic of China [n=205; 13.2%], Hong Kong 
[n=18; 1.2%], Malaysia [n=33; 2.1%], the Philippines 
[n=113; 7.3%], Taiwan [n=199; 12.8%], Thailand [n=17; 
1.1%], and Singapore [n=2; 0.1%]).
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Patients (outpatients) were eligible to participate in the 
study if they met the following inclusion criteria: 1) present-
ing with an episode of MDD within the normal course of 
care, with MDD diagnosed according to the International 
Statistical Classification of Diseases 10th revision (ICD-10)30 
or Diagnostic and Statistical Manual of Mental Disorders-
4th edition text revision (DSM-IV-TR)31 criteria; 2) at 
least moderately depressed, defined by the Clinical Global 
Impression-Severity (CGI-S) (with a score of $4);32 3) initi-
ating or switching to any available SSRI or SNRI antidepres-
sant, in accordance with a treating psychiatrist’s discretion; 
4) at least 18 years of age; 5) sexually active (with partner 
or autoerotic activity, including during the 2 weeks prior 
to study entry) without sexual dysfunction, as defined by 
Arizona Sexual Experience Scale;33 6) not participating in 
another currently ongoing study; and 7) providing consent 
to release data. The study excluded patients who had: 1) a 
history of treatment-resistant depression; 2) a past or current 
diagnosis of schizophrenia, schizophreniform, or schizoaf-
fective disorder, bipolar disorder, dysthymia, mental retarda-
tion, or dementia; or 3) received any antidepressant within 
1 week (1 month for fluoxetine) prior to study entry, with the 
exception of patients receiving an ineffective treatment for 
whom the immediate switch to an SSRI or SNRI antidepres-
sant was considered to be the best treatment option.
ethical approval
This study followed the ethical standards of responsible local 
committees and the regulations of the participating coun-
tries. Ethical Review Board (ERB) approval was obtained 
as required for observational studies wherever required by 
local law. The review boards included can be found in the 
Supplementary material. 
All patients also provided written informed consent for 
the provision and collection of the data. Further details of the 
study design have been published elsewhere.34–36
study therapy
Patients were prescribed any commercially available SSRI 
or SNRI in accordance with each country’s approved labels 
and at the discretion of the participating psychiatrist. Patients 
were not required to continue taking the medication initiated 
at baseline. Changes in medication and dosing were possible 
at any time as determined by the treating psychiatrist.
The present analysis included only those patients who 
initiated either duloxetine with a daily dose of #60 mg 
(duloxetine cohort) or an SSRI (SSRI cohort) at approved 
therapeutic dosages, both as monotherapy at baseline.
Data collection and outcome assessment
Data collection for the study occurred during visits within 
the normal course of care. The routine outpatient visit at 
which patients were enrolled served as the time for baseline 
data collection. Subsequent data collection was targeted 
at week 8, week 16, and week 24 since the baseline visit. 
Patient demographics and clinical history were recorded 
at the baseline assessment. Clinical severity of depression 
was assessed at each visit using the CGI-S32 and the 16-item 
Quick Inventory of Depressive Symptomatology Self-Report 
(QIDS-SR
16
).37
Functioning was also assessed at each visit using the SDS, 
which is a brief self-report inventory that assesses functional 
impairment in work/school, social life, and family life.28 
The level of functioning in each of the three domains was 
measured from 0 to 10 (0: no impairment, 1–3: mild impair-
ment, 4–6: moderate impairment, 7–9: marked impairment, 
10: extreme impairment). The level of global functioning was 
measured with the sum of the three subscores.
Depression-related pain severity was measured using 
the pain-related items of the Somatic Symptom Inventory 
(SSI), which included abdominal pain, lower back pain, joint 
pain, neck pain, heart/chest pain, headaches, and muscular 
soreness.38 PPS status was also assessed as PPS negative 
(PPS-) or positive (PPS+); PPS+ was defined as a mean 
score of $2 for the seven pain-related items of the SSI.
statistical analysis
This study included a total of 452 patients who 1) initiated 
either duloxetine with a daily dose of #60 mg or an SSRI 
as monotherapy at baseline for the treatment of MDD and 
2) who did not have missing data on the QIDS-SR
16
 score at 
baseline with at least one nonmissing QIDS-SR
16
 score during 
follow-up (n=227 in the duloxetine group and n=225 in the 
SSRI group). It also analyzed the patient observations up to 
the point where their initial medications were discontinued 
(n=176 [77.5%] in the duloxetine group and n=167 [74.2%] 
in the SSRI group available at 24 weeks).
Baseline patient characteristics as well as outcomes at 
each visit by initial treatments were described and compared 
using the chi-square test (for categorical variables) and 
Mann–Whitney test (for continuous variables).
The mean levels (raw values) of functioning (both total 
and subscores of the SDS) at each visit by treatment in the 
overall sample as well as in the subgroup of patients with 
PPS+ and PPS-, respectively, were also described and com-
pared using the Mann–Whitney test. The effect sizes were 
also calculated using Cohen’s d (ie, the difference in mean 
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values divided by a standard deviation)39 for the differences 
in the levels of functioning between the two treatment cohorts 
at each visit.
Adjusted mixed-effects modeling with repeated measures 
(MMRM) analysis was used to compare levels of functioning 
(SDS total, work, social life, and family life) during follow-up 
between the two treatment cohorts. The unstructured 
covariance pattern was used to model within-patient cor-
relation. These models were adjusted for age, sex, SSI pain 
score at baseline, QIDS-SR
16
 score at baseline, the baseline 
value of the outcome modeled, and visit number. In addition, 
the following variables were included for further adjustment 
if they appeared to be significant (P,0.1) in univariate 
analyses: independent living (living in his/her own house), 
living with a spouse/partner, employment status, having 
MDD episodes in the 24 months prior to study entry, MDD 
hospitalizations in the 24 months prior to study entry, and the 
number of any significant preexisting comorbidities. Finally, 
the models also included the interaction term between time 
(visit number) and treatment if it appeared to be significant 
(P,0.05) in the full model.
All analyses were repeated for subgroups of patients with 
and without PPS (ie, PPS+ and PPS- patients) to examine 
whether treatment effects on functioning vary by PPS status 
at baseline.
The differences between the two treatment cohorts were 
considered statistically significant with a P-value of ,0.05. 
All statistical analyses were performed using SAS Version 
9.3 for Windows (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics at study entry
A total of 452 patients were included in the final analysis. Over-
all, the mean (standard deviation [SD]) age of these patients 
was 37.5 (SD =10.8) years and 56.0% were female. More 
than one-third of the patients were from People’s Republic of 
China (n=165, 36.5%), followed by Taiwan (n=122, 27.0%) 
and the Philippines (n=108, 23.9%). In addition, almost half 
of the patients (n=201, 44.6%) had PPS at baseline.
Of the 452 patients, 227 initiated duloxetine with a daily 
dose of #60 mg at baseline and the rest (n=225) initiated an 
SSRI antidepressant at baseline. The most common SSRIs 
prescribed at baseline were paroxetine (29.3%), fluoxetine 
(23.6%), escitalopram (20.0%), and sertraline (12.9%). The 
median daily doses of these medications at baseline were 
20.0 mg/day for paroxetine, 10.0 mg/day for escitalopram, 
50.0 mg/day for sertraline, 20.0 mg/day for fluoxetine, and 
60.0 mg/day for duloxetine.
Table 1 summarizes the baseline patient characteristics by 
treatment cohorts. While sociodemographic characteristics 
were in general similar between the two cohorts, a higher 
proportion of the SSRI cohort was from People’s Republic 
of China. In addition, a lower proportion of them had PPS at 
baseline (51.1% in the duloxetine cohort and 37.9% in the SSRI 
cohort, P=0.005), and the mean SSI pain score at baseline was 
also lower in the SSRI cohort than in the duloxetine cohort. 
Nevertheless, the level of depression severity, as measured by 
CGI-S and QIDS-SR
16
, was similar between the two cohorts.
improvement in functioning by treatment 
cohort
Table 2 demonstrates the levels of functioning (raw means), 
as measured by SDS total and subscores, at baseline and 
at 24 weeks by treatment cohort. The levels of functional 
impairment were generally similar between the two treatment 
cohorts at baseline: the mean SDS total score at baseline 
was 15.46 (SD =6.11) in the duloxetine cohort and 16.36 
(SD =6.53) in the SSRI cohort (P=0.077). Specifically, both 
treatment cohorts, on average, exhibited a moderate level of 
functional impairment at baseline in all three inter-related 
domains (SDS work, social life, and family life), with the 
mean score of 4.91 (SD =2.30) (for family life) to 5.33 
(SD =2.28) (for work) in the duloxetine cohort and that of 
5.31 (SD =2.53) (for family life) to 5.54 (SD =2.45) (for 
work) in the SSRI cohort. While the mean SDS total score at 
baseline was also similar between the two treatment cohorts 
in the subgroup of PPS+ patients (16.76 [SD =6.35] in the 
duloxetine cohort and 16.96 [SD =7.11] in the SSRI cohort, 
P=0.546), it was slightly higher in the SSRI cohort in the 
subgroup of PPS- patients (14.09 [SD =5.56] in the former 
and 16.01 [SD =6.18] in the latter, P=0.013).
Despite similar levels of functioning at baseline between 
the two treatment cohorts in the overall sample as well as in 
the subgroup of PPS+ patients, duloxetine-treated patients 
achieved greater levels of functioning at 24 weeks, com-
pared to SSRI-treated patients. The mean SDS total score at 
24 weeks was 2.15 (SD =4.35) in the duloxetine cohort and 
4.69 (SD =4.88) in the SSRI cohort in the overall sample 
(P,0.001). The effect size of this treatment difference 
was -0.55. A higher level of functioning in the duloxetine 
cohort was also observed in all three SDS domains (work, 
social life, and family life) with the effect sizes of -0.46 
(social life) to -0.62 (work). The treatment difference 
was more apparent in the subgroup of PPS+ patients. The 
mean SDS total score at 24 weeks was 1.95 (SD =4.19) 
in the duloxetine cohort and 5.48 (SD =5.61) in the SSRI 
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Table 1 Baseline patient characteristics by treatment cohorts
Baseline characteristics Duloxetine (#60 mg per day) 
(n=227)
SSRI 
(n=225)
P-value
age, mean (sD) 37.7 (10.7) 37.4 (11.0) 0.712
Female, % 59.5 52.4 0.132
country, % ,0.001
hong Kong 0.4 6.2
Malaysia 7.0 7.1
Thailand 0.0 3.6
singapore 0.0 0.9
Taiwan 30.8 23.1
People’s republic of china 26.0 47.1
Philippines 35.7 12.0
Age at first symptoms of MDD, mean (SD) 35.5 (10.9) 34.7 (11.3) 0.403
BMi (kg/m2), mean (sD) 22.8 (3.5) 22.5 (3.2) 0.315
living with a spouse/partner, % 64.6 71.1 0.139
cgi-s, mean (sD) 4.3 (0.6) 4.4 (0.6) 0.092
QiDs-sr16, mean (sD) 14.0 (4.4) 14.2 (4.3) 0.622
ssi-pain, mean (sD) 14.5 (5.3) 12.8 (4.4) 0.001
Painful physical symptoms, % 51.1 37.9 0.005
Number of comorbidities, % 0.353
None 86.8 82.6
1 8.4 12.5
$2 4.8 4.9
had MDD episodes in the past 24 months, % 56.4 57.8 0.765
had been hospitalized for MDD in the past 24 months, % 4.0 8.0 0.070
Note: Data are presented as percentage or mean (sD) as appropriate.
Abbreviations: BMi, body mass index; cgi-s, clinical global impressions of severity; MDD, major depressive disorder; QiDs-sr16, 16-item Quick inventory of Depressive 
symptomatology self-report; sD, standard deviation; ssi-pain, somatic symptom inventory; ssri, selective serotonin reuptake inhibitor.
Table 2 Mean levels (raw values) of sDs total and subscores at baseline and at 24 weeks by treatment cohorts with and without PPs 
at baseline
Outcome Total PPS+ PPS-
Duloxetine SSRI Effect 
sizesa
Duloxetine SSRI Effect 
sizesa
Duloxetine SSRI Effect 
sizesa
at baseline
sDs total score 15.46 (6.11) 16.36 (6.53) -0.14 16.76 (6.35) 16.96 (7.11) -0.03 14.09 (5.56)b 16.01 (6.18)b -0.33
sDs work score 5.33 (2.28) 5.54 (2.45) -0.10 5.52 (2.39) 5.59 (2.55) -0.03 5.13 (2.16) 5.52 (2.40) -0.17
sDs social life score 5.20 (2.22) 5.48 (2.49) -0.12 5.59 (2.29) 5.62 (2.65) -0.01 4.80 (2.09)b 5.39 (2.39)b -0.26
sDs family life score 4.91 (2.30)b 5.31 (2.53)b -0.17 5.63 (2.22) 5.65 (2.68) -0.01 4.16 (2.16)b 5.11 (2.42)b -0.41
at 24 weeks
sDs total score 2.15 (4.35)b 4.69 (4.88)b -0.55 1.95 (4.19)b 5.48 (5.61)b -0.75 2.35 (4.54)b 4.37 (4.55)b -0.44
sDs work score 0.75 (1.48)b 1.74 (1.69)b -0.62 0.66 (1.37)b 1.93 (1.70)b -0.85 0.83 (1.59)b 1.67 (1.69)b -0.51
sDs social life score 0.75 (1.48)b 1.47 (1.66)b -0.46 0.69 (1.43)b 1.70 (1.97)b -0.62 0.81 (1.53)b 1.38 (1.51)b -0.38
sDs family life score 0.66 (1.48)b 1.44 (1.68)b -0.49 0.60 (1.46)b 1.70 (1.87)b -0.68 0.71 (1.49)b 1.33 (1.60)b -0.40
Notes: aThese show effect sizes of differences in functional impairment between treatment cohorts. bP,0.05 for the comparison of the outcome between the duloxetine 
cohort and the ssri cohort in the overall sample, PPs+ patients, and PPs- patients, respectively. Data are presented as mean (standard deviation).
Abbreviations: PPs, painful physical symptoms; sDs, sheehan Disability scale; ssri, selective serotonin reuptake inhibitor.
cohort in this subgroup (P,0.001), resulting in the effect 
size of -0.75. Similarly, a higher level of functioning in 
the duloxetine cohort was also observed in all three SDS 
domains, with the effect sizes of -0.62 (social life) to -0.85 
(work). Meanwhile, the treatment difference at 24 weeks in 
the subgroup of PPS- patients was similar to that observed 
at baseline, although both treatment cohorts achieved 
better functioning at 24 weeks. The mean SDS total score 
at 24 weeks was 2.35 (SD =4.54) in the duloxetine cohort 
and 4.37 (SD =4.55) in the SSRI cohort in this subgroup 
(P,0.001).
The superiority of duloxetine over SSRIs in terms of 
improvement in functioning was maintained even when 
the baseline differences between the two treatment cohorts 
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were adjusted for (Figure 1). Given the interaction term 
between time and treatment included in the MMRM models 
(Table 3), the interpretation of the coefficients of treat-
ment, time, and their interaction was not straightforward. 
Therefore, the (adjusted) mean SDS total scores (ie, least 
squares means) at each postbaseline visit by treatment 
cohorts were further estimated and presented in Figure 1. 
Consistent with the descriptive results, the MMRM results 
also showed higher levels of functioning in duloxetine-
treated patients than in SSRI-treated patients throughout 
follow-up (P,0.05 for all treatment comparisons at each 
postbaseline visit). At 24 weeks, the estimated mean SDS 
total score was 4.48 (standard error [SE] =0.80) in the 
duloxetine cohort, which was lower than that of 6.76 
(SE =0.77) in the SSRI cohort (P,0.001) (ie, better func-
tioning in the duloxetine cohort). As shown in Figure 2, the 
treatment difference, especially at latter follow-up visits, 
was again more apparent in the subgroup of PPS+ patients, 
whereas the treatment difference at baseline observed in 
the subgroup of PPS- patients remained relatively constant 
throughout follow-up in this subgroup. Similar patterns were 
observed in each of SDS domains (ie, work, social life, and 
family life) (data not shown).
Discussion
This post hoc analysis examined functioning in the subgroup 
of East Asian patients who were either treated with dulox-
etine with a daily dose of #60 mg or an SSRI for MDD for 
up to 6 months in actual clinical practice. The results showed 
that while this group of patients, on average, exhibited a mod-
erate level of functional impairment in all three interrelated 
SDS domains (work, social life, and family life) at baseline, 
their functioning improved substantially in all three domains 
during follow-up. In particular, duloxetine-treated patients 
achieved greater improvement in functioning compared to 
SSRI-treated patients. This treatment difference was mostly 
driven by the subgroup of patients with PPS at baseline.
effects of antidepressants on functioning
No published research has examined the comparative effec-
tiveness of duloxetine (or SNRIs) and SSRIs on functioning 
Figure 1 The estimated sDs total scores during follow-up by treatment cohorts.
Note: *The baseline scores are raw mean values.
Abbreviations: sDs, sheehan Disability scale; ssri, selective serotonin reuptake 
inhibitor.
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Table 3 The results of MMrM analyses: factors associated with sDs total scores during follow-up
Parameter Parameter estimate Standard error P-value
intercept 4.355 1.276 0.001
age -0.001 0.020 0.957
Female (vs male) 0.218 0.432 0.614
QiDs-sr16 score at baseline -0.056 0.063 0.375
ssi-pain score at baseline 0.010 0.048 0.842
sDs total score at baseline 0.312 0.042 ,0.001
comorbidities (vs none)
1 0.969 0.782 0.216
$2 0.813 1.294 0.530
had been hospitalized in the 24 months prior to baseline 3.441 1.213 0.005
had MDD episodes in the 24 months prior to baseline 0.500 0.443 0.259
Duloxetine (vs ssri) -1.361 0.536 0.012
Weeks (vs week 8)
Week 16 -1.997 0.381 ,0.001
Week 24 -4.376 0.441 ,0.001
Weeks × treatments
Duloxetine at week 16 -1.139 0.527 0.031
Duloxetine at week 24 -0.918 0.612 0.134
Abbreviations: MDD, major depressive disorder; MMrM, mixed-effects modeling with repeated measures; QiDs-sr16, 16-item Quick inventory of Depressive 
symptomatology self-report; sDs, sheehan Disability scale; ssi, somatic symptom inventory; ssri, selective serotonin reuptake inhibitor.
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in patients with MDD. Recently, however, several stud-
ies have examined the effects of antidepressants, mostly 
SNRIs, versus placebo on functioning.11,40–46 These studies, 
in general, have demonstrated greater effects of antide-
pressants compared to placebo, especially in subgroups of 
patients with MDD such as those with PPS or severely ill. 
Using pooled data from six randomized controlled trials 
(RCTs) in patients with MDD, Mancini et al40 reported 
the treatment difference of -2.52 between duloxetine and 
placebo in the SDS total score at the short-term end point 
(7–13 weeks), which was statistically significant in favor 
of duloxetine. More interestingly, they also presented the 
results of path analysis, which indicated that the effects 
of duloxetine on functioning is mainly mediated through 
its effect on depressive symptoms, as measured using the 
Hamilton rating scale for depression (HAMD),47 and PPS, 
as measured using a visual analog scale for pain severity 
(each ~40% of the total effect on functioning). This finding 
also partly explains the additional advantage of duloxetine 
on functioning in PPS+ patients observed in our study. 
The impact of depression and pain on functioning has also 
been demonstrated in another duloxetine study. Using data 
from a single-arm open-label study, this study assessed the 
relationship between functional improvement in the SDS 
total score and clinical outcomes of mood, pain, and anxiety 
.8 weeks after switching treatment to duloxetine in patients 
with MDD.48 The study showed significant improvement in 
functioning after switching to duloxetine. Such functional 
improvement appeared to be positively correlated with each 
of the clinical outcomes, but more so with mood and pain 
than with anxiety. The effects of duloxetine on functioning in 
patients with MDD were, however, challenged in an analysis 
of two clinical trials having similar protocols and comparable 
patient populations.41 Duloxetine appeared to be superior to 
placebo in improving the 17-item HAMD (HAMD
17
) work/
activities scores at week 8 in one trial but not in another, 
although it narrowly missed statistical significance in the 
latter (P=0.051).
There are also a few studies that have demonstrated the 
effects of the SNRIs levomilnacipran,42 venlafaxine,11 and 
desvenlafaxine43,44,46 on several types of functional outcomes 
in patients with MDD. Notably, the superiority of desvenla-
faxine over placebo on functioning was better observed in 
more severely ill patients. For instance, the superiority of des-
venlafaxine was not observed in the whole sample (P=0.067) 
but observed in the subgroup of more severely ill patients 
with MDD (P=0.017) in a 12-week RCT.43 Meanwhile, few 
studies have examined the effects of SSRIs on functioning.45 
Kocsis et al45 assessed long-term, maintenance psychosocial 
functioning in patients with chronic major and double depres-
sion. The patients included in this maintenance phase were 
those identified as responders at the end of prior 16-week con-
tinuous treatment with the SSRI sertraline. While long-term 
treatment with sertraline resulted in only modest additional 
improvement of psychosocial functioning over that achieved 
in the short-term phase, those taking placebo experienced 
substantial worsening in psychosocial functioning compared 
to those taking sertraline during the maintenance phase.
comparative effectiveness of 
antidepressants and role of depression-
related pain
The superiority of SNRIs, including duloxetine over SSRIs, 
in terms of other clinical outcomes, has not been well estab-
lished in the literature either. There is, however, limited 
evidence to support the additional advantage of SNRIs in 
subgroups of patients with MDD with PPS and/or more 
severely ill.
First of all, the findings of the previous study with the same 
data as those employed here demonstrated greater effects of 
duloxetine than SSRIs in terms of remission, response, and 
depressive symptoms, especially in patients with PPS at 
baseline.36 Notably, this study (thereby the present analysis 
as well) included those patients who were at least moderately 
depressed, defined by the CGI-S score of $4.
Similarly, Thase et al,26 using pooled data from six RCTs, 
found that although duloxetine and the two SSRIs (fluoxetine 
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Figure 2 The estimated sDs total scores during follow-up by treatment cohorts in 
patients with and without PPs at baseline.
Notes: P=0.546 for the difference in sDs total scores between the two treatment 
cohorts at baseline and P,0.001 at 24 weeks in the subgroup of PPs+ patients. 
P=0.013 at baseline and P=0.168 at 24 weeks in the subgroup of PPs- patients. *The 
baseline scores are raw mean values.
Abbreviations: sDs, sheehan Disability scale; PPs, painful physical symptoms; ssri, 
selective serotonin reuptake inhibitor.
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and paroxetine) were comparably efficacious overall, treatment 
with duloxetine was associated with higher remission rate in 
patients with moderate-to-severe depression (a HAMD
17
 score 
of $19). Similar findings were also reported with another 
SNRI, milnacipran, in Japan. A case–control comparison of 
milnacipran and the SSRI fluvoxamine in 202 outpatients with 
major depression in Japan found that although the overall 
response rates were similar between the two groups, there 
were significantly more responders in the milnacipran group 
than in the fluvoxamine group in more severely depressed 
patients (a HAMD
17
 score of .19) as well as in patients with 
high scores on the “agitation” and “insomnia” items of the 
HAMD
17
.49 In addition to these comparative studies, several 
placebo-controlled duloxetine studies have demonstrated 
its effects on controlling depression-related PPS,22–24 as also 
reflected in its treatment indications, such as fibromyalgia, 
DPNP, and chronic musculoskeletal pain approved in the 
United States as well as in many other countries worldwide. 
Such studies are rarely available for SSRIs.
Taken together, continuous treatment is important to 
maintain functional well-being in patients with MDD. There 
seems a clear link between depression-related pain and 
functional impairment. SNRIs, duloxetine in particular, may 
better help patients with MDD to return to a normal level 
of daily functioning, than SSRIs, at least in the subgroup of 
patients with PPS or more severely ill.
study limitations
These results should be interpreted in the context of the 
following study limitations. First, the data were drawn from 
an observational study. Although the MMRM analysis con-
trolled the baseline imbalance between the two treatment 
cohorts, it is not possible to control any unobserved imbal-
ance between the two cohorts. Second, as the primary objec-
tive of this observational study was to assess the frequency 
of treatment-emergent sexual dysfunction in the treatment 
of MDD, the study included only those patients who were 
sexually active without sexual dysfunction at baseline. 
Sexual dysfunction has been reported to be two to three 
times more prevalent in patients with depression compared 
to the general population,50,51 and thus, our findings may 
not be immediately generalizable to patients with MDD as 
a whole. Further research is warranted to examine whether 
these findings can be replicated in patients with MDD with-
out such inclusion/exclusion criteria. Third, although this 
observational study included .500 patients from East Asia, 
they may not be representative of patients with MDD in the 
region as a whole. Finally, a multiplicity of analyses was 
not adjusted for in these exploratory analyses. Our results 
therefore should be interpreted with caution until further 
replication is available.
Conclusion
Patients treated with duloxetine with a daily dose of 
#60 mg achieved higher levels of functioning (ie, global, 
work, social life, and family life), compared to those 
treated with SSRIs for the management of MDD in actual 
clinical practice settings in East Asia. As hypothesized, 
the superiority of duloxetine over SSRIs on functional 
outcomes appeared to be more pronounced in the subgroup 
of patients with PPS at baseline. This finding reaffirms 
the importance of pain management in the treatment of 
MDD, especially for MDD-related functional impairment, 
and also the additional advantage of duloxetine, possibly 
SNRIs as a whole, in the treatment of patients with MDD 
presenting with PPS.
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